Please provide your email address to receive an email when new articles are posted on . The FDA granted breakthrough device designation to Quest Diagnostics’ Haystack MRD test for identifying patients ...
Haystack MRD test detects minimal residual disease in stage 2 colorectal cancer patients post-surgery, using circulating tumor DNA (ctDNA) for less invasive monitoring. The FDA's breakthrough device ...
The FDA's Breakthrough Devices Program accelerates access to promising medical devices for serious conditions, ensuring safety and effectiveness through a rigorous review process. Haystack MRD test ...
SECAUCUS, N.J., Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has ...
(RTTNews) - Adaptive Biotechnologies Corp. (ADPT), Tuesday announced the launch of an enhanced version of its clonoSEQ assay for measurable residual disease or MRD detection in diffuse large B-cell ...
The US Food and Drug Administration (FDA) has granted breakthrough device designation for Quest Diagnostics’ Haystack minimal residual disease (MRD) test for colorectal cancer. Haystack is designed to ...
(RTTNews) - Quest Diagnostics (DGX), a provider of diagnostic information services, announced Monday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback